Article
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2016
Awad Mark M, Oxnard Geoffrey R, Jackman David M, Savukoski Daniel O, Hall Dimity, Shivdasani Priyanka, Heng Jennifer C, Dahlberg Suzanne E, Jänne Pasi A, Verma Suman, Christensen James, Hammerman Peter S, Sholl Lynette M
Abstract excerpt
PURPOSE: Non-small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical, pathologic, and genomic characteristics of patients with cancer with MET exon 14 mutations. PATIENTS AND METHODS: We interrogated next-generation sequencing results from 6,376 cancers to identify those harboring MET exon 14 mutations....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.